Surface marker expression of MO-MDSCs and PMN-MDSCs from EG7 and BW-Sp3 tumor–bearing mice
| . | MO-MDSC . | PMN-MDSC . | ||
|---|---|---|---|---|
| EG7 . | Sp3 . | EG7 . | Sp3 . | |
| Myeloid maturation markers | ||||
| CD34 | − | − | − | − |
| CD117 (c-kit) | − | − | − | − |
| Sca-1 (Ly6A/E)* | − | + | − | − |
| Myeloid lineage markers | ||||
| F4/80† | ++ | ++ | +/− | − |
| CD115 (M-CSFR)† | + | + | − | − |
| 7/4‡ | +++ | +++ | ++ +/− | ++ +/− |
| Monocyte/PMN subset markers | ||||
| CCR2‡ | ++ | ++ | + | + |
| CX3CR1 | − | − | − | − |
| CD62L | +++ | +++ | +++ | +++ |
| Ly6C‡ | +++ | +++ | ++ +/− | ++ +/− |
| Tie-2 | − | − | − | − |
| VLA-4 (CD49d)‡ | +++ | +++ | + | + |
| Adhesion molecules | ||||
| CD11a (LFA-1) | ++ | ++ | ++ | ++ |
| CD2 (LFA-2)† | + | + | − | − |
| CD31 (PECAM-1)† | + | + | − | − |
| CD162 (PSGL-1) | +++ | +++ | +++ | +++ |
| CD54 (ICAM-1)‡ | +++ | +++ | + | + |
| CD43 | +++ | +++ | +++ | +++ |
| CD44 | +++ | +++ | +++ | +++ |
| Pattern recognition receptors | ||||
| CD14 | − | − | − | − |
| CD204 (SR-A) | − | − | − | − |
| SIGN-R1 | − | − | − | − |
| MAC-2 (Galectin-3)‡ | ++ | ++ | + | + |
| Fc/complement receptors | ||||
| CD16/32 (FcγRIII/II) | + | + | + | + |
| CD23 (FcϵRII) | − | − | − | − |
| CD21/35 (CR2/CR1) | − | − | − | − |
| Antigen processing/presentation | ||||
| CD13 | − | − | − | − |
| CD40 | − | − | − | − |
| CD86 (B7–2) | − | − | − | − |
| CD1d† | + | + | − | − |
| MHC I | +++ | +++ | +++ | +++ |
| MHC II | − | − | − | − |
| Potential T cell–suppressive markers | ||||
| CD80 (B7–1) | ++ | ++ | ++ | ++ |
| B7H1 (PD-L1) | + | + | + | +/− |
| B7DC (PD-L2)* | +/− | − | +/− | − |
| B7H4 | − | − | − | − |
| MGL1/2† | + | + | − | − |
| Miscellaneous | ||||
| IL4Rα | + | + | + | + |
| CD71 (transferrin receptor)† | + | + | − | − |
| . | MO-MDSC . | PMN-MDSC . | ||
|---|---|---|---|---|
| EG7 . | Sp3 . | EG7 . | Sp3 . | |
| Myeloid maturation markers | ||||
| CD34 | − | − | − | − |
| CD117 (c-kit) | − | − | − | − |
| Sca-1 (Ly6A/E)* | − | + | − | − |
| Myeloid lineage markers | ||||
| F4/80† | ++ | ++ | +/− | − |
| CD115 (M-CSFR)† | + | + | − | − |
| 7/4‡ | +++ | +++ | ++ +/− | ++ +/− |
| Monocyte/PMN subset markers | ||||
| CCR2‡ | ++ | ++ | + | + |
| CX3CR1 | − | − | − | − |
| CD62L | +++ | +++ | +++ | +++ |
| Ly6C‡ | +++ | +++ | ++ +/− | ++ +/− |
| Tie-2 | − | − | − | − |
| VLA-4 (CD49d)‡ | +++ | +++ | + | + |
| Adhesion molecules | ||||
| CD11a (LFA-1) | ++ | ++ | ++ | ++ |
| CD2 (LFA-2)† | + | + | − | − |
| CD31 (PECAM-1)† | + | + | − | − |
| CD162 (PSGL-1) | +++ | +++ | +++ | +++ |
| CD54 (ICAM-1)‡ | +++ | +++ | + | + |
| CD43 | +++ | +++ | +++ | +++ |
| CD44 | +++ | +++ | +++ | +++ |
| Pattern recognition receptors | ||||
| CD14 | − | − | − | − |
| CD204 (SR-A) | − | − | − | − |
| SIGN-R1 | − | − | − | − |
| MAC-2 (Galectin-3)‡ | ++ | ++ | + | + |
| Fc/complement receptors | ||||
| CD16/32 (FcγRIII/II) | + | + | + | + |
| CD23 (FcϵRII) | − | − | − | − |
| CD21/35 (CR2/CR1) | − | − | − | − |
| Antigen processing/presentation | ||||
| CD13 | − | − | − | − |
| CD40 | − | − | − | − |
| CD86 (B7–2) | − | − | − | − |
| CD1d† | + | + | − | − |
| MHC I | +++ | +++ | +++ | +++ |
| MHC II | − | − | − | − |
| Potential T cell–suppressive markers | ||||
| CD80 (B7–1) | ++ | ++ | ++ | ++ |
| B7H1 (PD-L1) | + | + | + | +/− |
| B7DC (PD-L2)* | +/− | − | +/− | − |
| B7H4 | − | − | − | − |
| MGL1/2† | + | + | − | − |
| Miscellaneous | ||||
| IL4Rα | + | + | + | + |
| CD71 (transferrin receptor)† | + | + | − | − |
Expression of the indicated markers was evaluated on gated CD11b+Ly6C+Ly6G−(Gr-1+) MO-MDSC and CD11b+Ly6C+Ly6G+(Gr-1+) PMN-MDSC subfractions, relative to isotype-matched controls.
Markers differing between the 2 tumor models.
Markers expressed on MO-MDSCs but not on PMN-MDSCs.
Markers differentially expressed between MO- and PMN-MDSCs.